Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test - Roche Holding (OTC:RHHBY), Roche Holding (OTC:RHHBF), Roche Holding (OTC:RHHVF)

Roche Holdings AG RHHBY has launched the Elecsys HCV Duo immunoassay, the first available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
The test can detect the early stage of infection, when the patient is recovering from the virus or showing signs of a chronic infection that may lead to other diseases, such as liver cancer.
Also Read: Diagnostic Companies Focus On Monkeypox Tests Following Outbreak; Experts Do Not Count It As Next COVID Yet.
The Elecsys HCV Duo assay enables a significantly earlier diagnosis of active hepatitis C virus infection than antibody-only assays by utilizing the dual detection of HCV core antigen and antibodies to HCV.
In 2019, 58 million people in the world were living with chronic hepatitis C infection, but only 21% were aware of it, according to World Health Organization data. The disease can lead to death from conditions including cirrhosis and liver failure.
Price Action: RHHBY shares closed higher by 2.49% at $42.46 on Friday.